Home » Departments » Men's Health Update » Hypogonadism
Hypogonadism
The risk of hematocrit elevation may depend on testosterone therapy’s route of administration, according to investigators.
Most direct-to-consumer platforms offer testosterone therapy despite consumer reporting normal testosterone levels, free testosterone
Age-specific testosterone cutoffs show each 1-year increase in age tied to a 4.3-ng/dL decrease in testosterone level
A study was conducted to determine the cardiovascular safety of testosterone therapy for treatment of hypogonadism.
Odds of hospitalization higher for men receiving inadequate TTh versus those with normal testosterone concentration while receiving TTh
The FDA has approved Kyzatrex (testosterone undecanoate) for the treatment of primary and secondary hypogonadism in adult males.
No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety
Efforts to reduce obesity may cut the prevalence of these urological conditions.
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Load More
Open
Next post in Hypogonadism
Close
Close more info about Direct-to-Consumer Testosterone Not Offered in Accordance With Guidelines
Loading...
Close more info about Direct-to-Consumer Testosterone Not Offered in Accordance With Guidelines
Loading...